Skip to content
Canine PeptideResearch peptides

References

Every factual claim on this site traces to one of the studies below. Canine-specific studies are marked — there are fewer of them than the volume of discussion about these compounds would suggest, and that gap is itself worth knowing.

The short answer

This guide cites 45 peer-reviewed studies, of which 5 were conducted in dogs. The rest are rodent, equine, in vitro, or human studies from which canine relevance is inferred. That distinction is the single most important thing to understand about the evidence base in this field.

Canine studies (5)

  1. 1.CANINE STUDYHe L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588717
  2. 2.CANINE STUDYXu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
  3. 3.CANINE STUDYGary AT, Kerl ME, Wiedmeyer CE, et al. Bone marrow hypoplasia associated with fenbendazole administration in a dog. Journal of the American Animal Hospital Association, 2004. PMID 15131104
  4. 4.CANINE STUDYPetronzio A, Carabetta D, Koid A Bone marrow toxicity associated with febantel administration in a dog: Case Report. Frontiers in Veterinary Science, 2025. PMID 40260210
  5. 5.CANINE STUDYDiao H, Cheng N, Zhao Y, et al. Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling. BMC Veterinary Research, 2019. PMID 31375107

All references (45)

  1. 1.Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine, 2026. PMID 41476424
  2. 2.Biçer O, Adanır O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery, 2026. PMID 42542926
  3. 3.Vasireddi N, Nguyen HH, Ahmed WA, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025. PMID 40756949
  4. 4.Józwiak M, Bauer M, Kamysz W, Kleczkowska P Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals, 2025. PMID 40005999
  5. 5.CANINE STUDYPetronzio A, Carabetta D, Koid A Bone marrow toxicity associated with febantel administration in a dog: Case Report. Frontiers in Veterinary Science, 2025. PMID 40260210
  6. 6.Pan T, et al. Fenbendazole induces pyroptosis in breast cancer cells through HK2/caspase-3/GSDME signaling. Frontiers in Pharmacology, 2025. PMID 40756987
  7. 7.Morinaga S, Han Q, Mizuta K, et al. Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer Cells. Anticancer Research, 2025. PMID 39740811
  8. 8.Nguyen J, Chong CR Oral Fenbendazole for Cancer Therapy in Humans and Animals. Anticancer Research, 2024. PMID 39197912
  9. 9.Delcourt V, Loup B, Bailly-Chouriberry L, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and unapproved drugs. Drug Testing and Analysis, 2023. PMID 36482504
  10. 10.Wei Y, Zhang J, Yan X, et al. Thymosin α-1 in cancer therapy: Immunoregulation and potential applications. International Immunopharmacology, 2023. PMID 36812669
  11. 11.Jung H, Lee J, Kim Y, et al. Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Models of Mouse Lymphoma. Current Issues in Molecular Biology, 2023. PMID 37998737
  12. 12.CANINE STUDYHe L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588717
  13. 13.Sarafraz-Yazdi E, Pincus MR, Michl J PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis. Biomedicines, 2022. PMID 35625682
  14. 14.Tang M, Hu X, Wang Y, et al. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacological Research, 2021. PMID 32971268
  15. 15.CANINE STUDYXu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
  16. 16.Dominari A, Hathaway Iii D, Pandav K, et al. Thymosin alpha 1: A comprehensive review of the literature. World Journal of Virology, 2020. PMID 33362999
  17. 17.Juarez M, Schcolnik-Cabrera A, Dominguez-Gomez G, et al. Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug. Cancer Chemotherapy and Pharmacology, 2020. PMID 32474842
  18. 18.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
  19. 19.CANINE STUDYDiao H, Cheng N, Zhao Y, et al. Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling. BMC Veterinary Research, 2019. PMID 31375107
  20. 20.Wang F, Yu T, Zheng H, Lao X Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life. Scientific Reports, 2018. PMID 30120362
  21. 21.Pickart L, Margolina A Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018. PMID 29986520
  22. 22.Dogra N, Kumar A, Mukhopadhyay T Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports, 2018. PMID 30093705
  23. 23.Juarez M, Schcolnik-Cabrera A, Dueñas-Gonzalez A The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. American Journal of Cancer Research, 2018. PMID 29511601
  24. 24.Hsieh M-J, Liu H-T, Wang C-N, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 2017. PMID 27847966
  25. 25.Kleinman HK, Sosne G Thymosin β4 Promotes Dermal Healing. Vitamins and Hormones, 2016. PMID 27450738
  26. 26.King R, Tuthill C Immune Modulation with Thymosin Alpha 1 Treatment. Vitamins and Hormones, 2016. PMID 27450734
  27. 27.Guo Y, Chang H, Li J, et al. Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway. Apoptosis, 2015. PMID 26002438
  28. 28.Pickart L, Vasquez-Soltero JM, Margolina A GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015. PMID 26236730
  29. 29.Davitt K, Babcock BD, Fenelus M, et al. The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells. Annals of Clinical and Laboratory Science, 2014. PMID 25117093
  30. 30.Duan Q, Liu Y, Rockwell S Fenbendazole as a potential anticancer drug. Anticancer Research, 2013. PMID 23393324
  31. 31.Xu B, Yang M, Li Z, et al. Thymosin beta4 enhances the healing of medial collateral ligament injury in rat. Regulatory Peptides, 2013. PMID 23523891
  32. 32.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 2012. PMID 22074294
  33. 33.Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma. Journal of Chromatography A, 2012. PMID 23084823
  34. 34.Kandalla PK, Goldspink G, Butler-Browne G, Mouly V Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mechanisms of Ageing and Development, 2011. PMID 21354439
  35. 35.Chang C-H, Tsai W-C, Hsu Y-H, Pang J-HS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 2011. PMID 21030672
  36. 36.Philp D, Kleinman HK Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences, 2010. PMID 20536453
  37. 37.Sarafraz-Yazdi E, Bowne WB, Adler V, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. PNAS, 2010. PMID 20080680
  38. 38.Sookraj KA, Bowne WB, Adler V, et al. The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide. Cancer Chemotherapy and Pharmacology, 2010. PMID 20182728
  39. 39.Goldspink G Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology, 2005. PMID 16024511
  40. 40.CANINE STUDYGary AT, Kerl ME, Wiedmeyer CE, et al. Bone marrow hypoplasia associated with fenbendazole administration in a dog. Journal of the American Animal Hospital Association, 2004. PMID 15131104
  41. 41.Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 2004. PMID 15565145
  42. 42.Canapp SO Jr, Farese JP, Schultz GS, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery, 2003. PMID 14648529
  43. 43.Cha H-J, Jeong M-J, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. Journal of the National Cancer Institute, 2003. PMID 14625258
  44. 44.Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology, 1999. PMID 10469335
  45. 45.Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation, 1993. PMID 8227353